Intensifying Salvage Treatment Reduces Risk of Prostate Cancer Progression
Short-term androgen deprivation therapy alone or in combination with pelvic lymph node radiotherapy can improve the efficacy of prostate bed radiotherapy.
Short-term androgen deprivation therapy alone or in combination with pelvic lymph node radiotherapy can improve the efficacy of prostate bed radiotherapy.
Disease-free survival and overall survival rates were similar with 3 months or 6 months of adjuvant chemotherapy.
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
Patients with pancreatic cancer were 3 times more likely to have gallstone disease in the year prior to their cancer diagnosis, when compared with non-cancer patients.
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
The incidence of esophageal cancer nearly doubled, and this was not due to an increase in screening.
Immunotherapy prolonged survival compared with platinum chemotherapy.
A rectum-preserving strategy may produce outcomes similar to standard resection-based treatment for locally advanced rectal adenocarcinoma.
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.